Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study
BackgroundUnderstanding the predictors of metabolic disorders in persons with HIV/HCV coinfection post-HCV therapy is crucial for improving patient outcomes. Since immune checkpoint proteins are usually upregulated in these persons with HIV/HCV coinfection, we aimed to evaluate the association betwe...
Saved in:
Similar Items
-
PBMCs gene expression predicts liver fibrosis regression after successful HCV therapy in HIV/HCV-coinfected patients
by: Ana Virseda-Berdices, et al.
Published: (2025-01-01) -
Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study
by: Daniel Sepúlveda-Crespo, et al.
Published: (2024-08-01) -
Persistent Low Anti-HIV Neutralizing Antibody Titers in HIV/HCV Coinfection Despite HCV Cure: A 5-Year Longitudinal Analysis
by: Daniel Sepúlveda-Crespo, et al.
Published: (2025-05-01) -
The best anti-HCV S/Co values for reflecting HCV infection in a university hospital in the eastern part of Turkey
by: Bülent Dabanlıoğlu, et al.
Published: (2024-01-01) -
Threshold value of the anti-HCV test in the diagnosis of HCV infection
by: Özlem Kirişci, et al.
Published: (2019-10-01)